{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-006289","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.025680+00:00","generated_at":"2026-06-05T05:56:54.812303+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GeoVax reports 2023 net loss of $26.0M, cash drops to $6.5M; pipeline advances","bullets":["Net loss widened to $26.0M in 2023 from $14.0M in 2022, driven by higher R&D costs ($20.7M vs $9.1M).","Cash balance fell to $6.5M at Dec 31, 2023, from $27.6M a year earlier, reflecting clinical spending.","Phase 2 trials of Covid vaccine GEO-CM04S1 continue; interim CLL booster data expected H1 2024.","Gedeptin Phase 1/2 for head & neck cancer completed; expanded Phase 2 plans anticipated in 2024.","Appointed Dr. J. Marc Pipas as Executive Medical Director, Oncology, to lead clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-006289","json":"https://secwatch.observer/filing/0001437749-24-006289.json","markdown":"https://secwatch.observer/filing/0001437749-24-006289.md","text":"https://secwatch.observer/filing/0001437749-24-006289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774924006289/0001437749-24-006289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774924006289/govx20240228_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:56:54.812303+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77eeb5bdbbc16d3ef422394da9127dd8c554802b","claim":"GeoVax Labs, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774924006289/0001437749-24-006289-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}